Ragistomig can simultaneously target programmed death-ligand 1 (PD-L1) and the 4-1BB receptor. Ragistomig elicits potent anti-tumor T-cell responses without inducing significant toxicity. Ragistomig is applicable for tumor research[1].
Molecular Weight:
(199.524 kDa)
Purity:
97.469
CAS Number:
[2763222-58-6]
Target:
PD-1/PD-L1
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
